The present inventor, when administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, an increase in the number of platelets of a certain value or more is observed, and when a sufficient number of platelets can be secured, subsequent administration It was found that excessively increasing the number of platelets can be prevented by discontinuing the procedure while securing the effect of increasing the number of platelets.本発明者は、トロンボポエチン受容体アゴニスト作用を有する化合物を含有する医薬組成物の投与中に一定値以上の血小板数の増加が見られかつ、十分な血小板数が確保できている場合、以後の投与を中止することにより、血小板数の増加効果を確保しつつ、血小板数の過剰な増加を防止できることを見出した。
